Central European Institute of Technology Masaryk University Brno Czech Republic University Hospital Brno Brno Czech Republic

Department of Immunology Genetics and Pathology Science for Life Laboratory Uppsala University Uppsala Sweden

Department of Immunology Genetics and Pathology Science for Life Laboratory Uppsala University Uppsala Sweden Institute of Applied Biosciences Center for Research and Technology Hellas Thessaloniki Greece Hematology Department Hematopoietic Cell Transplantation Unit G Papanicolaou Hospital Thessaloniki Greece

Division of Haematology Department of Translational Medicine Amedeo Avogadro University of Eastern Piedmont Novara Italy

Institute of Applied Biosciences Center for Research and Technology Hellas Thessaloniki Greece

Università Vita Salute San Raffaele Milan Italy Division of Experimental Oncology Department of Onco Hematology Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele Milan Italy

Università Vita Salute San Raffaele Milan Italy Division of Experimental Oncology Department of Onco Hematology Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele Scientific Institute Milan Italy

Blood. 2016 Mar 24;127(12):1611-3. doi: 10.1182/blood-2015-10-678490. PubMed

Zobrazit více v PubMed

Puente XS, Pinyol M, Quesada V, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature. 2011;475(7354):101–105. PubMed PMC

Wang L, Lawrence MS, Wan Y, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med. 2011;365(26):2497–2506. PubMed PMC

Baliakas P, Hadzidimitriou A, Sutton LA, et al. European Research Initiative on CLL (ERIC) Recurrent mutations refine prognosis in chronic lymphocytic leukemia. Leukemia. 2015;29(2):329–336. PubMed

Jeromin S, Weissmann S, Haferlach C, et al. SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients. Leukemia. 2014;28(1):108–117. PubMed

Rossi D, Rasi S, Spina V, et al. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood. 2013;121(8):1403–1412. PubMed PMC

Martínez-Trillos A, Pinyol M, Navarro A, et al. Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome. Blood. 2014;123(24):3790–3796. PubMed

Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94(6):1840–1847. PubMed

Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94(6):1848–1854. PubMed

Baliakas P, Hadzidimitriou A, Sutton LA, et al. Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study. Lancet Haematol. 2014;1(2):74–84. PubMed

Lin KI, Tam CS, Keating MJ, et al. Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens. Blood. 2009;113(14):3168–3171. PubMed PMC

Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY

Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact

Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia

Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors